RT Journal Article
SR Electronic
T1 S29 Prognostic Value Of Platelet Count In Patients Admitted With An Acute Exacerbation Of Copd (aecopd)
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP A17
OP A17
DO 10.1136/thoraxjnl-2014-206260.35
VO 69
IS Suppl 2
A1 Echevarria, C
A1 Steer, J
A1 Gibson, GJ
A1 Bourke, SC
YR 2014
UL http://thorax.bmj.com/content/69/Suppl_2/A17.1.abstract
AB Introduction In an observational cohort of patients admitted with AECOPD, thrombocytosis was associated with inpatient and 1-year mortality.1 We aimed to validate, and explore mechanisms for, this association within our original DECAF cohort (n = 920).2 Methods Admission platelet counts were categorised as low (<150), normal (150–400), or high (>400) x109 cells/mm3 and odds ratios assessed for inpatient and, among those surviving to discharge, 1-year mortality (normal platelet count=reference). For inpatient mortality, platelet category and DECAF indices were included in multivariate logistic regression. The areas under the ROC curves for DECAF and DECAF+Platelets were compared by the method of DeLong. Associations with thrombocytosis were analysed using Mann-Whitney or Fisher’s exact test. Causes of death at 1-year due to respiratory, cardiac or malignant disease were recorded. Results Thrombocytosis was associated with inpatient (OR 1.83, 95% CI 1.12–3.00, p = 0.016) and 1-year mortality (OR 1.62 95% CI 1.09–2.30, p = 0.017). Thrombocytopenia was associated with inpatient (OR 3.5, 95% CI 1.51–8.12, p = 0.004), but not 1-year mortality (OR 1.81, 95% CI 0.76–4.312.08, p = 0.181). On multivariate analysis, thrombocytosis (OR 1.85, 95% CI 1.03–3.33 p = 0.039) and thrombocytopenia (OR 3.00 95% CI 1.09–8.24 p = 0.033) independently predicted inpatient mortality, but did not improve predictive power of DECAF (AUROC: DECAF=0.86, DECAF+Platelets=0.86; p = 0.93). Thrombocytosis was associated with a higher white cell count (p<0.001) and eMRCD score (i.e. more breathless when stable; p = 0.001), lower: albumin (p = 0.004), BMI (p = 0.002), FEV1 (p = 0.010), haemoglobin (p<0.001), and a lower proportion of women (p = 0.004), and patients with eosinopenia (<0.05 x 109/l) (p = 0.008), cardiac death (p = 0.044), current smoking (p = 0.046), AF (p = 0.029) and diabetes (p = 0.006). Thrombocytosis was not related to cardiovascular disease, prior exacerbation and readmission rates or LTOT use, admission PaO2, pH or NIV, or length of stay. Discussion Thrombocytosis was an independent predictor of both inpatient mortality and, amongst survivors to discharge, 1-year mortality. Thrombocytosis was not associated with cardiovascular disease and the higher 1-year mortality was not due excess cardiovascular or cancer deaths, suggesting that other mechanisms are responsible. Whilst thrombocytosis was not associated with LTOT use or PaO2, it was associated with other indices of disease severity, including breathlessness and lower FEV1, BMI and albumin level. ReferencesHarrison Thorax 2014 Steer Thorax 2012 View this table:Abstract S29 Table 1 Platelet category and cause of death